The identification of predictive biomarkers—such as circulating tumor DNA, DNA damage response signatures, STING pathway activation, and cytokine profiles—may enable personalized treatment planning and improve the monitoring of therapeutic response (Cristescu et al., 2018; Kim et al., 2016). This evidence concerns the gene STING1 and neoplasm.